Absci Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 0/6
Absci şirketinin kazançları yıllık ortalama -4% oranında azalırken, Biotechs sektörünün kazançları yıllık 33.4% oranında artan oldu. Gelirler yıllık ortalama 14.9% oranında azalan oldu.
Anahtar bilgiler
-4.02%
Kazanç büyüme oranı
28.43%
EPS büyüme oranı
| Biotechs Sektör Büyümesi | 17.04% |
| Gelir büyüme oranı | -14.86% |
| Özkaynak getirisi | -49.19% |
| Net Marj | -7,756.37% |
| Son Kazanç Güncellemesi | 30 Jun 2026 |
Yakın geçmiş performans güncellemeleri
Recent updates
Seeking Alpha • Sep 08
Absci: Positive Ph1 Data ABS-201 AGA And Several Catalysts Inbound (Upgrade)
Summary Absci Corporation is upgraded to “Buy” following positive interim Phase 1 data for ABS-201 in androgenetic alopecia [AGA]. ABS-201 demonstrated an excellent PK profile, enabling infrequent dosing [2–3 injections per 6 months] and strong safety/tolerability in SAD cohorts. Upcoming catalysts include 13-week interim proof-of-concept data in 2H 2026 and 26-week topline results in early 2027 for ABS-201 in AGA. ABSI is well-capitalized post-$93.6M offering, with expansion plans for ABS-201 in endometriosis and ABS-202 in preclinical I&I indications. Read the full article on Seeking Alpha
Anlatı Güncellemesi • Jul 24
ABSI: Hair Loss And Endometriosis Readouts Will Drive The Next Phase
Analysts have raised their blended Absci price target from about $10 to roughly $17, citing stronger views on the potential of lead asset ABS-201 after positive interim Phase 1 data, expanded modeled sales in endometriosis and androgenetic alopecia, and reduced near-term balance sheet risk following recent financing. Analyst Commentary Recent research coverage on Absci centers on how quickly ABS-201 has moved from a platform proof point to the key driver of valuation, with price targets and models now increasingly tied to the drug's potential in androgenetic alopecia and endometriosis.
Anlatı Güncellemesi • Jul 10
ABSI: Interim Hair Loss Data And Funding Will Drive Repricing Ahead
The Absci analyst price target has moved higher, with fair value rising from $12.40 to about $13.78 as analysts factor in positive interim ABS-201 data, expanded sales assumptions in endometriosis, and reduced near term balance sheet risk following recent financing. Analyst Commentary Recent research on Absci highlights a mix of optimism around ABS-201 and its AI platform, alongside clear reminders of execution and clinical risk.Anlatı Güncellemesi • Jun 26
ABSI: Interim Hair Loss Data And Financing Will Drive Repricing Ahead
Absci's updated analyst price target now reflects a move from $8.11 to $12.40, with analysts pointing to positive interim ABS-201 data, expanded indications such as endometriosis, and reduced near term balance sheet risk as key drivers of their revised valuation work. Analyst Commentary Analyst commentary on Absci centers on how far the ABS-201 program and the broader AI-driven platform can carry the valuation, with price targets across the Street now clustered well above prior levels.Analiz Makalesi • Jun 19
Absci (ABSI) Stock Could Be 63% Overvalued After Leerink Starts Coverage
Absci (ABSI) drew fresh attention after Leerink initiated coverage, highlighting the company’s AI native, clinical stage drug pipeline, including ABS-20 and ABS-201, and pointing to 2026 as a potentially important clinical data year. See our latest analysis for Absci. Absci’s recent coverage has coincided with strong momentum, with a 30 day share price return of 60.04% and a 90 day share price return of 150.34%. The 1 year total shareholder return of 169.45% points to strong longer term...Analiz Makalesi • Apr 04
We Think Absci (NASDAQ:ABSI) Needs To Drive Business Growth Carefully
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Analiz Makalesi • Jul 19
Does Absci (NASDAQ:ABSI) Have A Healthy Balance Sheet?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Seeking Alpha • Jan 13
Absci Looks Cheap And Positioned For Growth With AMD's AI Backing
Summary Absci recently received a $20 million PIPE investment from AMD that improves its runway and R&D platform with AI. ABS-101 appears to be ABSI’s main drug candidate for IBD. However, ABS-201 for hair loss and ABS-301 for solid tumors offer additional sizeable TAMs if successful. ABSI’s AI models and wet lab data seem quite promising for discovering further antibodies that could be highly differentiated from other competitors. ABSI trades at a cheap P/B of 1.5, so I don’t think the shares have priced in the potential of its partnership with AMD yet. My main concern is that ABSI operates with highly speculative technologies, and its candidates remain in the early R&D stages. Read the full article on Seeking AlphaSeeking Alpha • Nov 20
Absci Corporation: Struggling To Live Up To Its AI Promise
Summary Absci Corporation's stock has rebounded due to new collaborations, but skepticism about AI's impact on drug discovery keeps it heavily underwater from its IPO price. Absci uses AI and wet lab technologies to speed up drug discovery, aiming to reduce preclinical periods to under two years. Despite partnerships with Merck, AstraZeneca, and others, Absci's revenue remains minimal, and it has no advanced pipeline assets yet. With a market cap just over $300 million and cash runway into 1H27, Absci is a speculative play in the AI drug discovery space. An analysis around Absci Corporation follows in the paragraphs below. Read the full article on Seeking AlphaAnaliz Makalesi • Nov 13
Is Absci (NASDAQ:ABSI) A Risky Investment?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Seeking Alpha • Oct 29
Absci: Embryonic Pipeline Looks Expensive Relative To Peers
Summary Absci's differentiated drug discovery platform could create significant shareholder value long term. The company has a long and expensive path to traverse before it can prove the merits of its approach though. While cash burn is currently limited, Absci's operations are ramping, meaning increased costs could begin to pressure the share price in the future. Absci has largely avoided the growing pessimism towards AI-enabled drug discovery companies and is beginning to look expensive relative to peers as a result. Read the full article on Seeking AlphaSeeking Alpha • Oct 03
Absci: AI-Driven Platform Could Establish Best-In-Class TL1A Drug Targeting Profile
Summary Absci Corporation's initiation of a phase 1 study using ABS-101 for the treatment of patients with IBD expected early 2025, with interim data to be released in the 2nd half of 2025. ABS-101 aims to differentiate itself with unique features like de novo antibody creation, multiparameter lead optimization, and reverse immunology, potentially offering superior potency and dosing flexibility. The global Crohn's Disease treatment market is expected to reach $17.80 billion by 2033. The ulcerative colitis treatment market is expected to reach $14.77 billion by 2033. Read the full article on Seeking AlphaSeeking Alpha • Jul 28
Absci Corporation Leverages AI For Rapid Drug Discovery And Promising Partnerships
Summary Absci Corporation uses IDCP technology to quickly produce high-quality drug candidates in as little as six weeks, reducing costs and improving research success rates. The company has promising candidates in inflammatory bowel disease, dermatology, and immuno-oncology, attracting major partnerships with over $900 million in deal value and royalties. ABSI focuses on three therapeutic areas: inflammatory bowel disease, dermatology, and immuno-oncology. Investors should be aware of the high risks due to the speculative nature of AI-driven drug discovery and potential funding needs. Still, ABSI trades at a reasonable valuation, making it a sound speculative "buy" for investors aware of biotech's inherent risks. Read the full article on Seeking AlphaAnaliz Makalesi • Jun 17
Is Absci (NASDAQ:ABSI) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Seeking Alpha • May 16
Absci: 'AI' Tag Keeping Company Afloat While Searching For Right Formula
Summary Absci Corporation, an AI-driven drug discovery company, has seen its share price plummet after its IPO in July 2021. Nearly all AI-driven drug discovery companies have struggled with overall share price performance since IPO. Absci's stock has been picking up - +250% across the past six months - thanks to investment in the sector, and a recently agreed partnership with AstraZeneca. Merck is another Big Pharma partner, but these deals don't guarantee revenues and with development programs preclinical, it's difficult to assign much value. Without its "AI" tag, Absci would likely be a $100m - $200m market cap valuation company. The company may show its mettle in time, but the prospect of near term revenues, or further upside, seems remote in 2024. Read the full article on Seeking AlphaSeeking Alpha • Feb 27
Absci: Differentiated Antibody Discovery Play
Summary Absci combines generative AI with scalable wet lab technologies to improve antibody discovery, with the eventual goal of in silico drug design. While Absci's stock has benefitted from AI hype in recent months, the company has substance. Its approach to antibody drug development is unique and could have advantages. Absci's valuation is still reasonable given the company's long-term potential, but the stock price is likely to be tied to AI sentiment in the near term, creating downside risk. Read the full article on Seeking AlphaGelir ve Gider Dağılımı
Gelir ve Gider Dağılımı
Absci nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
| Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
|---|---|---|---|---|
| 30 Jun 26 | 2 | -121 | 35 | 0 |
| 31 Mar 26 | 2 | -118 | 35 | 0 |
| 31 Dec 25 | 3 | -115 | 35 | 0 |
| 30 Sep 25 | 3 | -115 | 35 | 0 |
| 30 Jun 25 | 4 | -113 | 36 | 0 |
| 31 Mar 25 | 5 | -107 | 37 | 0 |
| 31 Dec 24 | 5 | -103 | 36 | 0 |
| 30 Sep 24 | 4 | -98 | 37 | 0 |
| 30 Jun 24 | 3 | -92 | 37 | 0 |
| 31 Mar 24 | 5 | -109 | 37 | 0 |
| 31 Dec 23 | 6 | -111 | 38 | 0 |
| 30 Sep 23 | 7 | -106 | 36 | 0 |
| 30 Jun 23 | 9 | -112 | 38 | 0 |
| 31 Mar 23 | 6 | -99 | 39 | 0 |
| 31 Dec 22 | 6 | -105 | 41 | 0 |
| 30 Sep 22 | 6 | -111 | 42 | 0 |
| 30 Jun 22 | 5 | -107 | 39 | 0 |
| 31 Mar 22 | 5 | -121 | 34 | 0 |
| 31 Dec 21 | 5 | -103 | 28 | 0 |
| 30 Sep 21 | 6 | -84 | 21 | 0 |
| 30 Jun 21 | 5 | -73 | 14 | 0 |
| 31 Mar 21 | 5 | -48 | 9 | 0 |
| 31 Dec 20 | 5 | -49 | 6 | 0 |
| 31 Dec 19 | 2 | -24 | 4 | 0 |
Kaliteli Kazançlar: ABSI şu anda kârlı değil.
Büyüyen Kar Marjı: ABSI şu anda kârlı değil.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: ABSI kârlı değildir ve zararlar son 5 yılda yılda 4% oranında artmıştır.
Büyüme Hızlandırma: ABSI 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil
Kazançlar vs. Sektör: ABSI kârlı olmadığından, geçmiş yıl kazanç büyümesinin Biotechs sektörüyle ( 64.6% ) karşılaştırılması zorlaşıyor.
Özkaynak Getirisi
Yüksek ROE: ABSI hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -49.19% ) sahiptir.
Varlık Getirisi
Kullanılan Sermaye Getirisi
Geçmişte güçlü performans gösteren şirketleri keşfedin
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/09/21 16:26 |
| Gün Sonu Hisse Fiyatı | 2026/09/18 00:00 |
| Kazançlar | 2026/06/30 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Absci Corporation 15 Bu analistlerden 10, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Michael Ryskin | BofA Global Research |
| Kambiz Yazdi | BTIG |
| Vamil Divan | Guggenheim Securities, LLC |